Evaluating Medical Cannabis Reimbursement in Workers’ Compensation

A Pioneering Model for Safety and Equity in Colorado

Co-Authors: Dr. Xavier James Ethan Moses, Blair Ilsley, MS, Megan Greenlee, MEd, Katherine Golden, RN, Dr. Alan E. Shackelford, Mariya Cassin, JD, Dr. Maggie Cook-Shimanek, Roy Foster, PhD, Emily Grayek, PhD, and Juliana Hill, MPH.

The Colorado Division of Workers’ Compensation (DOWC) developed a first-of-its-kind evaluation of a medical cannabis reimbursement model called the Alternative Pain Management Program. Published in the Journal of Occupational and Environmental Medicine (JOEM), this program evaluation explores whether integrating medical cannabis into a highly supervised clinical structure can offer a safe, equitable alternative for specific injured workers.

The Core Mission: Safety & Equity

This program was not a clinical trial to prove or disprove medical cannabis efficacy. Instead, it was a quality improvement project designed to address two long-standing gaps in workers’ compensation:

Bridging the Safety Gap: Many injured workers handle chronic pain through self-directed, unstructured cannabis use, often keeping it hidden from their primary doctors. This program brings cannabis use into the light, allowing for routine medical oversight, drug reconciliation, and safety tracking.
Addressing the Equity Gap: Access to alternative therapies shouldn't be limited to individuals who can afford to pay completely out of pocket after traditional medical treatments have hit their therapeutic limits.

How the Coordinated Care Model Works

The success of this model relied on intensive care coordination, bringing medical cannabis use under strict clinical oversight, utilizing a structured reimbursement framework rather than an open-ended "pay for weed" policy.

Strict Participant Eligibility: Of the over 200 legacy claimants screened, only one participant met the rigorous baseline criteria to ensure safety and compliance.

Divided Medical Oversight: The participant's Authorized Treating Physician (ATP) retained absolute clinical responsibility and handled routine screenings. Concurrently, a specialized medical cannabis physician managed dosing, titration, and cannabinoid ratios.
Reimbursed vs. Excluded Products: To minimize respiratory risks and maintain standardized dosing, only specific long-acting oral preparations (like precisely dosed gummies) were approved for reimbursement. Inhaled, smoked, or vaporized formulations were strictly excluded from reimbursement.
Digital Tracking: The participant used a mobile cannabis-tracking app (TetragramⓇ) to log product adherence and report real-time insights to the care team.

Program Results & Key Outcomes

The program evaluated outcome measures over a 12-month timeline:

Meaningful Life Improvements: Data revealed clear, measurable reductions in pain alongside significant improvements in physical function, overall mobility, and quality of life.
Zero Adverse Events: The structured care framework yielded zero adverse safety events or concerning drug interactions. Psychological status was monitored throughout the 12-month evaluation and remained stable.
Voluntary Opioid Tapering: The primary goal of the study was not opioid reduction, and no mandatory tapers were enforced. However, due to improved symptom control under clinical supervision, the participant voluntarily reduced monthly opioid intake by 17%. (Note: Since the final compilation of the study's data, the participant successfully transitioned off both opioids and THC completely, relying only on less psychoactive cannabinoids.)

Understanding the Limitations

As a preliminary proof-of-concept, it is critical to evaluate this model within its boundaries:

Single-Participant Sample: Because this evaluation followed a single individual, the results cannot yet be generalized system-wide or applied broadly to the general public.
Non-Working Status: The program participant was fully retired. Future iterations must carefully study the safety implications for active workforces, specifically excluding individuals operating in safety-sensitive employment roles.
Resource Intensive: The high level of ongoing clinical advocacy and specialized interagency coordination requires scalable infrastructure to expand.

Questions or Accessibility Inquiries?

To learn more about the Division of Workers' Compensation's alternative programs, please contact the DOWC communications team at cdle_dowc_communications@state.co.us.